J&J Zarnestra Receives “Not Approvable” Letter From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”
You may also be interested in...
Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
Johnson & Johnson On Track For Eight NME Filings, Approvals In 2007
Firm plans to submit a follow-on to the recently approved antipsychotic Invega by year-end.
Johnson & Johnson On Track For Eight NME Filings, Approvals In 2007
Firm plans to submit a follow-on to the recently approved antipsychotic Invega by year-end.